OBJECTIVE: Toll-like receptors (TLR) bridge innate immunity and host responses, including inflammation. Sterile inflammation such as a venous thrombus (Vt) may involve TLR signaling, including TLR9. METHODS AND RESULTS: TLR9 signaling on thrombus resolution was investigated using a mouse model of stasis Vt. Vt were significantly larger in TLR9-/- mice compared with wild-type (WT) at 2 and 8 days, despite a 2-fold increase in thrombus polymorphonucleic neutrophils at 2 days and monocytes at 8 days, whereas thrombus collagen and neovascularization was 55% and 37% less, respectively, at 8 days. Coincidently, decreased fibrinogen and increased thrombin-antithrombin complex were observed in TLR9-/- mouse thrombi. Vein wall interferon-α, interleukin-1α, and interleukin-2 were significantly reduced in TLR9-/- mice compared with WT. Thrombus cell death pathway markers were not significantly altered at 2 days, but caspase-1 was reduced in TLR9-/- thrombi at 8 days. MyD88 confers TLR9 intracellular signaling, but MyD88-/- mice had Vt resolution similar to that of WT. However, inhibition of the NOTCH ligand δ-like 4 was associated with larger Vt. Finally, stimulation with a TLR9 agonist was associated with smaller Vt. CONCLUSIONS: TLR9 signaling is integral for early and mid-Vt resolution through modulation of sterile inflammation, maintaining a TH1 milieu, and effects on the thrombosis pathway.
OBJECTIVE: Toll-like receptors (TLR) bridge innate immunity and host responses, including inflammation. Sterile inflammation such as a venous thrombus (Vt) may involve TLR signaling, including TLR9. METHODS AND RESULTS:TLR9 signaling on thrombus resolution was investigated using a mouse model of stasis Vt. Vt were significantly larger in TLR9-/- mice compared with wild-type (WT) at 2 and 8 days, despite a 2-fold increase in thrombus polymorphonucleic neutrophils at 2 days and monocytes at 8 days, whereas thrombus collagen and neovascularization was 55% and 37% less, respectively, at 8 days. Coincidently, decreased fibrinogen and increased thrombin-antithrombin complex were observed in TLR9-/- mouse thrombi. Vein wall interferon-α, interleukin-1α, and interleukin-2 were significantly reduced in TLR9-/- mice compared with WT. Thrombus cell death pathway markers were not significantly altered at 2 days, but caspase-1 was reduced in TLR9-/- thrombi at 8 days. MyD88 confers TLR9 intracellular signaling, but MyD88-/- mice had Vt resolution similar to that of WT. However, inhibition of the NOTCH ligand δ-like 4 was associated with larger Vt. Finally, stimulation with a TLR9 agonist was associated with smaller Vt. CONCLUSIONS:TLR9 signaling is integral for early and mid-Vt resolution through modulation of sterile inflammation, maintaining a TH1 milieu, and effects on the thrombosis pathway.
Authors: Melvin M Denis; Neal D Tolley; Michaeline Bunting; Hansjörg Schwertz; Huimiao Jiang; Stephan Lindemann; Christian C Yost; Frederick J Rubner; Kurt H Albertine; Kathryn J Swoboda; Carolyn M Fratto; Emilysa Tolley; Larry W Kraiss; Thomas M McIntyre; Guy A Zimmerman; Andrew S Weyrich Journal: Cell Date: 2005-08-12 Impact factor: 41.582
Authors: Kristopher B Deatrick; Jonathan L Eliason; Erin M Lynch; Andrea J Moore; Nicholas A Dewyer; Manu R Varma; Charles G Pearce; Gilbert R Upchurch; Thomas W Wakefield; Peter K Henke Journal: J Vasc Surg Date: 2005-07 Impact factor: 4.268
Authors: Peter K Henke; Andrea Varga; Sumit De; C Barry Deatrick; Jonathon Eliason; Douglas A Arenberg; Pasu Sukheepod; Porama Thanaporn; Steven L Kunkel; Gilbert R Upchurch; Thomas W Wakefield Journal: Arterioscler Thromb Vasc Biol Date: 2004-04-22 Impact factor: 8.311
Authors: Peter K Henke; Manu R Varma; K Barry Deatrick; Nicholas A Dewyer; Nicholas A Drewyer; Erin M Lynch; Andrea J Moore; Derek A Dubay; Pasu Sukheepod; Charles G Pearce; Gilbert R Upchurch; Steven L Kunkel; Michael G Franz; Thomas W Wakefield Journal: Thromb Haemost Date: 2006-02 Impact factor: 5.249
Authors: Nicholas A Dewyer; Osama M El-Sayed; Catherine E Luke; Megan Elfline; Nicolai Kittan; Ron Allen; Adriana Laser; Carson Oostra; Anthony Comerota; Cory Hogaboam; Steven L Kunkel; Peter K Henke Journal: Thromb Haemost Date: 2015-07-16 Impact factor: 5.249
Authors: Allan K Metz; Jose A Diaz; Andrea T Obi; Thomas W Wakefield; Daniel D Myers; Peter K Henke Journal: Methodist Debakey Cardiovasc J Date: 2018 Jul-Sep
Authors: Osama M El-Sayed; Nicholas A Dewyer; Catherine E Luke; Megan Elfline; Adriana Laser; Cory Hogaboam; Steven L Kunkel; Peter K Henke Journal: J Vasc Surg Date: 2015-10-23 Impact factor: 4.268
Authors: Jose A Diaz; Andrea T Obi; Daniel D Myers; Shirley K Wrobleski; Peter K Henke; Nigel Mackman; Thomas W Wakefield Journal: Arterioscler Thromb Vasc Biol Date: 2012-03 Impact factor: 8.311
Authors: Crystal M Ripplinger; Chase W Kessinger; Chunqiang Li; Jin Won Kim; Jason R McCarthy; Ralph Weissleder; Peter K Henke; Charles P Lin; Farouc A Jaffer Journal: Arterioscler Thromb Vasc Biol Date: 2012-09-20 Impact factor: 8.311
Authors: Kristopher B Deatrick; Catherine E Luke; Megan A Elfline; Vikram Sood; Joseph Baldwin; Gilbert R Upchurch; Farouc A Jaffer; Thomas W Wakefield; Peter K Henke Journal: J Vasc Surg Date: 2013-03-13 Impact factor: 4.268